129.46 USD
+0.18 (+0.14%)
129.5 USD
+0.04 (+0.03%)
ChartMill assigns a Buy % Consensus number of 68% to BPMC. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 132.96. This target is 2.71% above the current price.
BPMC was analyzed by 25 analysts. The buy percentage consensus is at 68. So analysts seem to be have mildly positive about BPMC.
In the last month the buy percentage fell by 12 points. So the trust of analysts is decreasing.
BPMC was analyzed by 25 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-06-17 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2025-06-05 | UBS | Maintains | Neutral -> Neutral |
| 2025-06-05 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-06-04 | Citigroup | Upgrade | Sell -> Neutral |
| 2025-06-03 | Wolfe Research | Downgrade | Outperform -> Peer Perform |
| 2025-06-03 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2025-06-03 | Stephens & Co. | Downgrade | Overweight -> Equal-Weight |
| 2025-06-02 | ScotiaBank | Downgrade | Sector Outperform -> Sector Perform |
| 2025-06-02 | Needham | Downgrade | Buy -> Hold |
| 2025-06-02 | Wedbush | Downgrade | Outperform -> Neutral |
| 2025-06-02 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2025-05-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-28 | Needham | Maintains | Buy -> Buy |
| 2025-04-16 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-04-08 | Needham | Reiterate | Buy -> Buy |
| 2025-03-17 | Jefferies | Initiate | Buy |
| 2025-03-07 | ScotiaBank | Initiate | Sector Outperform |
| 2025-03-03 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-14 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-14 | Needham | Reiterate | Buy -> Buy |
| 2025-02-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-13 | Needham | Reiterate | Buy -> Buy |
| 2025-02-04 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-01-27 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2025-01-15 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-01-13 | Needham | Reiterate | Buy -> Buy |
| 2025-01-13 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-01-02 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2024-12-11 | Guggenheim | Reiterate | Buy -> Buy |
| 2024-12-09 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
BLUEPRINT MEDICINES CORP / BPMC FAQ
What do analysts expect the price target to be for BLUEPRINT MEDICINES CORP (BPMC)?
25 analysts have analysed BPMC and the average price target is 132.96 USD. This implies a price increase of 2.71% is expected in the next year compared to the current price of 129.46.
What is the consensus rating for BLUEPRINT MEDICINES CORP (BPMC) stock?
The consensus rating for BLUEPRINT MEDICINES CORP (BPMC) is 68 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
Can you provide the analyst count for BLUEPRINT MEDICINES CORP stock?
The number of analysts covering BLUEPRINT MEDICINES CORP (BPMC) is 25.